Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cadence Design Systems Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Cadence Design Systems Inc trades at $371.23 (market cap $102.34B). The key difference: Cadence Design Systems Inc is far larger — about 22.8× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | CDNS | |
|---|---|---|
Market Cap | $4.49B | $102.34B |
Sector | Health | Technology |
52-Week High | $28.06 | $416.39 |
52-Week Low | $20.06 | $265.66 |
Enterprise Value | $3.69B | $104.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Cadence Design Systems (CDNS) trades at $371.06, down 0.56% on the day, with strong analyst support showing 84% buy ratings and a $395.88 consensus price target. The stock demonstrates robust fundamentals with consistent earnings beats, 86% gross margins, and 21% net income margins. Recent technical analysis shows neutral momentum with support at $370 and resistance at $380. The company benefits from AI-driven semiconductor design demand and recently announced expanded collaboration with Intel Foundry.
CDNS presents a compelling growth story with strong profitability and market positioning in EDA software. The primary investment thesis centers on sustained AI-driven demand for chip design tools, though elevated valuation multiples (P/E 87.6) require continued execution. Key risks include semiconductor cycle volatility and competitive pressures from Synopsys. Upside potential exists if the company maintains its earnings beat streak and capitalizes on AI infrastructure spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
